Company intelligence / Profile preview

CITIC Capital

Hong Kong, Hong Kong, China

Ownership: Private
Employees: ~550
Development stage: Other

Overview

CITIC Capital manages over USD$16–20 billion in assets, investing in healthcare, medical devices, biotechnology, pharma, and related sectors. Recent transactions include buyouts and strategic investments in major OTC pharmaceutical manufacturers, plasma-based biotherapeutics, and hospitals, and it has a portfolio influencing hundreds of healthcare programs via controlling interest or equity stakes.

Therapeutic areas: Women's HealthOncologyInfectious Diseases
Modalities: Small moleculeBiologicAntibodyVaccineDrug delivery devices
Industry: Investors

Partnerships

Harbin Pharmaceutical GroupGNCGuilong PharmaceuticalTaibang Biologic GroupGenesis MedTechMedAllianceChinese public hospitalstop medical experts

Beyond the preview

Go deeper on CITIC Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CITIC Capital.

Explore the full profile